GSK
NYSE:GSKPharmaLondon, United Kingdom · Est. 2000 · 70,000 employees
Global biopharma company uniting science, technology, and talent.
110
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
104
Indications↗
Distinct diseases across all programs
3,771
Clinical Trials↗
All sponsored trials (all statuses)
23
Orange Book Patents
Across 3 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
110 drugs in development
Approved10
Phase 344
Phase 235
Phase 150
Preclinical12
By Therapeutic Area
top 6
Infectious Disease
5336%
Oncology
2316%
Immunology
1611%
Respiratory
117%
Nephrology
85%
Gastroenterology
53%
R&D Momentum
98/100
Pipeline Velocity
79/100
Trial Completion Rate
90/100
Pipeline Concentration
19/100
Pipeline Freshness
67/100
Strategic Signals
- ↗Active in Dermatology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Aug 28, 2026
Recruiting
A Phase 1, Open-Label, Randomized, Parallel-Group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations After a Single Dose in Healthy Participants
Aug 27, 2026
Recruiting
A Phase 3, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Depemokimab (GSK3511294) Administered Subcutaneously as Add on Maintenance Treatment of Asthma With Type 2 Inflammation Characterised by an Eosinophilic Phenotype in Participants Aged 6 to 11 Years Old
Aug 27, 2026
Active, not recruiting
A Phase 1, Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants
Aug 26, 2026
Recruiting
A Phase 2, Multicenter, Open Label, Non-randomized Study to Evaluate the Efficacy and Safety of Extended Dosing of Belantamab Mafodotin in Different Combinations With Standard of Care Regimens in Participants With Relapsed-refractory Multiple Myeloma (DREAMM-15)
Aug 25, 2026
Completed
A Phase I, First-Time-in Human (FTiH), Open-label, Dose Escalation, Non-randomized Study to Assess Safety, Reactogenicity and Immune Response of a CoV-2 SAM (LNP) Vaccine When Administered Intramuscularly on a 0, 1 Month Schedule in Healthy Adults 18 to 50 Years of Age
Aug 22, 2026
Active, not recruiting
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Aug 22, 2026
Completed
A Randomized, Non-inferiority, Double-blind, Controlled, Single-dose, 2-way Cross-over Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Metered Dose Inhalers in Adults Aged 18-45 With Mild Asthma
Details
Company Info
Company Overview
$80.0B
Mkt Cap
$30.3B
Revenue
$4.2B
Cash
CEOEmma Walmsley
Founded2000
Employees70,000
HQLondon, United Kingdom
ExchangeNYSE:GSK
Websitegsk.com
LinkedInCompany Page
Therapeutic Focus
Metabolic & EndocrineInfectious DiseasePsychiatryCardiovascularOncologyOtherImmunologyNeurologyHematologyDermatologyOphthalmologyRare DiseaseNephrologyGastroenterologyRespiratoryMusculoskeletal
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular(4 drugs)
1
—
1
—
2
Cardiovascular(4 drugs)
Dermatology(1 drug)
—
—
—
1
—
Dermatology(1 drug)
Gastroenterology(5 drugs)
—
—
2
2
1
Gastroenterology(5 drugs)
Immunology(16 drugs)
—
3
4
9
—
Immunology(16 drugs)
Infectious Disease(53 drugs)
—
17
19
25
6
Infectious Disease(53 drugs)
Metabolic & Endocrine(3 drugs)
—
1
1
—
1
Metabolic & Endocrine(3 drugs)
Musculoskeletal(1 drug)
1
—
—
—
—
Musculoskeletal(1 drug)
Nephrology(8 drugs)
—
4
3
1
—
Nephrology(8 drugs)
Neurology(3 drugs)
1
2
—
1
1
Neurology(3 drugs)
Oncology(23 drugs)
8
10
11
9
—
Oncology(23 drugs)
Respiratory(11 drugs)
—
5
3
4
2
Respiratory(11 drugs)
Unknown / Other(19 drugs)
1
10
4
4
3
Unknown / Other(19 drugs)
Regulatory
Regulatory Timeline
19821 event
FDANov 9
Potassium Chloride 0.037% In Sodium Chloride 0.9% In Plastic Container — SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER
Application NDA018722 (NDA)
19881 event
FDAOct 17
Potassium Chloride 0.037% In Sodium Chloride 0.9% In Plastic Container — POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Application NDA019686 (NDA)
19891 event
FDASep 29
Potassium Chloride 0.037% In Sodium Chloride 0.9% In Plastic Container — POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Application NDA019708 (NDA)
19961 event
FDAOct 28
Soriatane — SORIATANE
Application NDA019821 (NDA)
19971 event
FDAApr 4
Rescriptor — RESCRIPTOR
Application NDA020705 (NDA)
19982 events
FDADec 17
Ziagen — ZIAGEN
Application NDA020977 (NDA)
FDADec 17
Ziagen — ZIAGEN
Application NDA020978 (NDA)
20021 event
FDANov 26
Potassium Chloride 0.037% In Sodium Chloride 0.9% In Plastic Container — POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%
Application NDA017648 (NDA)
20031 event
FDAOct 20
Lexiva — LEXIVA
Application NDA021548 (NDA)
20071 event
FDAJun 14
Lexiva — LEXIVA
Application NDA022116 (NDA)
20163 events
FDANov 4
Selzentry — SELZENTRY
Application NDA208984 (NDA)
FDANov 4
Selzentry — SELZENTRY
Application NDA022128 (NDA)
FDAJun 9
Tivicay — TIVICAY
Application NDA204790 (NDA)
20202 events
FDAJun 12
Tivicay — TIVICAY PD
Application NDA213983 (NDA)
FDAApr 28
Bafiertam — BAFIERTAM
Application NDA210296 (NDA)
20212 events
FDADec 20
Cabenuva — APRETUDE
Application NDA215499 (NDA)
FDAJan 21
Cabenuva — VOCABRIA
Application NDA212887 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)